We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$1B
AUM Growth
+$47.9M
Cap. Flow
+$3.61M
Cap. Flow %
0.36%
Top 10 Hldgs %
53.49%
Holding
65
New
7
Increased
13
Reduced
12
Closed
4

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$12M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$10.2M
3
HRTX icon
Heron Therapeutics
HRTX
+$9.31M
4
VTRS icon
Viatris
VTRS
+$7.96M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$7.48M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$15.3M
2
HOLX
Hologic
HOLX
+$9.94M
3
IBB icon
iShares Biotechnology ETF
IBB
+$8.51M
4
PRGO icon
Perrigo
PRGO
+$8.4M
5
CELG
Celgene Corp
CELG
+$6.02M

Sector Composition

Rank Sector Weight
1 Healthcare 87.13%
2 Financials 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALR
26
DELISTED
Alere Inc
ALR
$9.84M 0.98%
286,540
-83,013
-22% -$3.03M
EIGR
27
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$9.83M 0.98%
+2,157
New +$10.2M
HRTX icon
28
Heron Therapeutics
HRTX
$94.1M
$9.69M 0.97%
+696,597
New +$9.31M
IRWD icon
29
Ironwood Pharmaceuticals
IRWD
$614M
$9.46M 0.95%
917,052
– –
SGNT
30
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$9.46M 0.95%
404,731
+85,500
+27% +$1.87M
IPXL
31
DELISTED
Impax Laboratories, Inc.
IPXL
$9.11M 0.91%
344,683
– –
ENDP
32
DELISTED
Endo International plc
ENDP
$8.66M 0.87%
126,215
– –
ALKS icon
33
Alkermes
ALKS
$8.39B
$8.59M 0.86%
194,870
– –
QCOR
34
DELISTED
QUESTCOR PHARMA INC
QCOR
$7.6M 0.76%
+117,080
New +$7.48M
RVTY icon
35
Revvity
RVTY
$12.7B
$7.46M 0.75%
165,495
+139,195
+529% +$6.11M
TMO icon
36
Thermo Fisher Scientific
TMO
$214B
$7.17M 0.72%
59,660
+49,680
+498% +$5.91M
ARAY icon
37
Accuray
ARAY
$33.9M
$7.03M 0.7%
731,943
– –
NBIX icon
38
Neurocrine Biosciences
NBIX
$18.7B
$6.89M 0.69%
427,790
– –
IDXX icon
39
Idexx Laboratories
IDXX
$44.1B
$6.83M 0.68%
112,530
– –
UNH icon
40
UnitedHealth
UNH
$383B
$6.76M 0.68%
82,436
– –
IPCI
41
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$6.18M 0.62%
140,400
– –
BDSI
42
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$5.77M 0.58%
683,260
+101,400
+17% +$818K
PCYC
43
DELISTED
PHARMACYCLICS INC
PCYC
$5.53M 0.55%
55,125
-42,875
-44% -$5.57M
ACOR
44
DELISTED
Acorda Therapeutics
ACOR
$4.28M 0.43%
941
– –
INFI
45
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.16M 0.42%
349,899
– –
ALNY icon
46
Alnylam Pharmaceuticals
ALNY
$27.4B
$4.13M 0.41%
61,595
+12,900
+26% +$999K
MOH icon
47
Molina Healthcare
MOH
$10.2B
$3.94M 0.39%
105,000
– –
MACK
48
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$3.82M 0.38%
96,221
– –
CNC icon
49
Centene
CNC
$30.1B
$3.73M 0.37%
240,000
– –
AEGR
50
DELISTED
Aegerion Pharmaceuticals
AEGR
$3.35M 0.33%
+72,520
New +$4.25M
1
2
3

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2014 Portfolio in Review

As of Q1 2014, Tekla Capital Management held 65 positions worth $1B, up 5% from $952M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Tekla Capital Management's Q1 2014 filing shows 7 new, 13 increased, 12 reduced and 4 closed positions. Its largest new stake was Eiger BioPharmaceuticals, Inc.: 2,157 shares worth $9.83M. The largest sale was Regeneron Pharmaceuticals, an estimated $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Financials.

  • Tekla Capital Management's largest Q1 2014 buy was Eiger BioPharmaceuticals, Inc.: 2,157 shares worth $9.83M.
  • Tekla Capital Management added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $12M increase.
  • Tekla Capital Management's biggest Q1 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $15.3M.
  • Tekla Capital Management fully exited Hologic in Q1 2014, selling an estimated $9.94M.
  • Tekla Capital Management's ten largest holdings make up 53% of its $1B portfolio in Q1 2014.
  • Tekla Capital Management opened 7 new positions and closed 4 in Q1 2014.
  • Tekla Capital Management's portfolio value rose 5% quarter-over-quarter to $1B.

Based on Tekla Capital Management's 13F filing for Q1 2014, filed 13 May 2014.